Leen Kawas Leads Propel With Vast Experience
Leen Kawas is a well-known leader in the biotech industry, known for her extensive experience and expertise in the field. She currently serves as the CEO of Propel, a biotechnology company that focuses on developing treatments for rare diseases. Here’s a closer look at her background and experience:
Education and early career
Leen Kawas earned her Bachelor of Science degree in pharmacy from the Jordan University of Science and Technology, followed by a PhD in pharmaceutical sciences from the University of California, San Francisco. She began her career in the biotech industry as a research scientist at Genentech, where she worked on the development of drugs for cancer and autoimmune diseases.
Over the years, Kawas has held a number of leadership roles in the biotech industry. She has served as the Vice President of Cytokinetics, where she was responsible for the development of treatments for neuromuscular diseases. She also served as the Chief Operating Officer of M3 Biotechnology, where she oversaw the development of drugs for Alzheimer’s and Parkinson’s diseases.
Entrepreneurship and innovation
Kawas has a passion for entrepreneurship and innovation, and has been involved in a number of startups over the years. She co-founded Aelan Cell Technologies, a biotech company that focused on developing treatments for neurological disorders, and served as the CEO of M3 Biotechnology before joining Propel.
Commitment to rare diseases
Throughout her career, Leen Kawas has demonstrated a strong commitment to developing treatments for rare diseases. She is passionate about finding new ways to help patients who have limited treatment options, and has worked tirelessly to advance research in this area.
Overall, Leen Kawas brings a wealth of experience and expertise to her role as the CEO of Propel. Her commitment to innovation, entrepreneurship, and finding new treatments for rare diseases has made her a respected leader in the biotech industry.